Tambon Nai Mueang

Researchers are evaluating the effectiveness of the tetravalent dengue vaccine (TDV) in reducing hospital stays due to dengue virus infections among children and adolescents in Southeast Asian countries with high dengue transmission, specifically Thailand, Indonesia, and Malaysia. This study focuses on participants aged 6 to 12 years who are part of a community-based cohort and may or may not receive TDV as part of a pilot public vaccination program. The research aims to provide further information on TDV's effectiveness, especially against the less common dengue virus types DENV-3 and DENV-4. This is a non-interventional study where participants are observed over a period of three years. Some cohort members may receive the TDV vaccine as part of a public vaccination program, while others may not be vaccinated. Researchers will compare hospitalization rates due to dengue between vaccinated and unvaccinated participants, without administering any study-specific treatments or interventions. Participants will be followed individually for three years, with their health monitored to identify any hospital stays caused by dengue infections. Blood samples may be collected at baseline and during illness episodes to confirm dengue infection using laboratory tests like RT-PCR. The primary outcome measured is hospitalization due to virologically confirmed dengue of any serotype. The study also includes matched case-control analyses within the cohort to better understand vaccine effectiveness and safety.

Atrial fibrillation (AF) is a common heart rhythm disorder that can lead to serious complications like stroke and bleeding. Asian patients with AF tend to have higher rates of major bleeding, including bleeding in the brain, compared to non-Asian patients. This research focuses on understanding the use of blood-thinning medications called anticoagulants, especially newer drugs known as non-vitamin K antagonist oral anticoagulants (NOACs), which are considered safer than warfarin but are less commonly used in Asian countries due to cost concerns. The study aims to track changes in how these medications are used and how they affect health outcomes over time. The study is a large, prospective observational registry conducted across 33 centers in Thailand, enrolling 3680 patients with non-valvular AF over two years. There is no intervention or treatment assigned by the study; instead, researchers observe patients' current treatments and outcomes. Participants will be followed every six months for a total of three years to monitor their use of warfarin and NOACs and record any serious events such as stroke, systemic embolism, major bleeding, heart attacks, heart failure, and overall quality of life. Throughout the study, patients will undergo regular assessments including clinical evaluations and monitoring of their medication use. The main outcomes measured over the three years include rates of using warfarin and NOACs, occurrence of ischemic stroke or transient ischemic attack, systemic embolism, intracranial hemorrhage, and major bleeding events. This long-term follow-up aims to provide valuable information on treatment patterns and safety in Asian patients with atrial fibrillation.

Peptic ulcer bleeding is the most common cause of upper gastrointestinal bleeding worldwide. After successful endoscopic hemostasis, proton pump inhibitors (PPIs) are recommended to prevent rebleeding. This trial evaluates a high-dose, locally made oral omeprazole compared to the standard intravenous PPI treatment for peptic ulcer bleeding. The study aims to determine if oral omeprazole is not inferior to intravenous PPI in preventing rebleeding and will also monitor gastric pH over 24 hours. Participants will be randomly assigned to one of two treatment groups after successful therapeutic endoscopy. One group will receive high-dose oral omeprazole, 40 mg twice daily for 72 hours, while the other group will receive a standard continuous intravenous drip of pantoprazole at 8 mg per hour for 72 hours. Both treatments are given immediately after randomization to assess their effectiveness in preventing ulcer rebleeding. During the study, researchers will monitor the rate of peptic ulcer rebleeding over three days as the primary outcome. Additional assessments include gastric pH monitoring for 24 hours. The study involves close observation after endoscopic hemostasis and treatment, with a focus on safety and treatment efficacy in patients with high-risk peptic ulcer bleeding.